MCID: SBP001
MIFTS: 49

Subependymal Giant Cell Astrocytoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Subependymal Giant Cell Astrocytoma

MalaCards integrated aliases for Subependymal Giant Cell Astrocytoma:

Name: Subependymal Giant Cell Astrocytoma 12 53 59 37 15 73
Sega 12 53 59
Astrocytoma Subependymal Giant Cell 55

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5077
MeSH 44 D001254
NCIt 50 C3696
SNOMED-CT 68 1586004 449799008
Orphanet 59 ORPHA251618
UMLS via Orphanet 74 C0205768
ICD10 via Orphanet 34 D43.2
KEGG 37 H01692
UMLS 73 C0205768

Summaries for Subependymal Giant Cell Astrocytoma

MalaCards based summary : Subependymal Giant Cell Astrocytoma, also known as sega, is related to tuberous sclerosis 1 and gemistocytic astrocytoma, and has symptoms including headache and seizures. An important gene associated with Subependymal Giant Cell Astrocytoma is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are mTOR signaling pathway and Angiopoietin Like Protein 8 Regulatory Pathway. The drugs Afinitor and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and endothelial, and related phenotype is behavior/neurological.

Wikipedia : 76 Subependymal giant cell astrocytoma (SEGA, SGCA, or SGCT) is a low-grade astrocytic brain tumor... more...

Related Diseases for Subependymal Giant Cell Astrocytoma

Diseases related to Subependymal Giant Cell Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 tuberous sclerosis 1 31.8 TSC1 TSC2
2 gemistocytic astrocytoma 30.8 GFAP S100B
3 obstructive hydrocephalus 30.5 GFAP SYP
4 angiomyolipoma 30.5 MTOR TSC1 TSC2
5 kidney angiomyolipoma 30.3 MTOR TSC1 TSC2
6 giant cell glioblastoma 30.2 GFAP SYP
7 hydrocephalus 28.8 ENO2 GFAP NES SYP
8 tuberous sclerosis 28.7 GFAP MTOR S100B SYP TSC1 TSC2
9 central neurocytoma 28.6 ENO2 GFAP NES SYP
10 dysembryoplastic neuroepithelial tumor 28.3 GFAP NES S100B SYP
11 subependymoma 27.8 ENO2 GFAP NES SYP TSC2
12 astrocytoma 11.1
13 primitive neuroectodermal tumor of the cervix uteri 10.7 ENO2 GFAP
14 melanotic medulloblastoma 10.7 ENO2 GFAP
15 cerebellar medulloblastoma 10.7 ENO2 GFAP
16 plexiform schwannoma 10.7 ENO2 GFAP
17 microcystic meningioma 10.6 ENO2 GFAP
18 hemimegalencephaly 10.6 GFAP MTOR
19 dysgerminoma of ovary 10.6 ENO2 GFAP
20 hepatic angiomyolipoma 10.5 MTOR TSC2
21 syringocystadenoma papilliferum 10.5 GFAP S100B
22 bednar tumor 10.5 ENO2 S100B
23 spindle cell rhabdomyosarcoma 10.5 GFAP S100B
24 myxopapillary ependymoma 10.5 GFAP S100B
25 juvenile pilocytic astrocytoma 10.5 ENO2 GFAP
26 chordoid glioma 10.5 GFAP S100B
27 epithelioid malignant peripheral nerve sheath tumor 10.5 ENO2 S100B
28 middle cerebral artery infarction 10.5 ENO2 S100B
29 syringoma 10.5 GFAP S100B
30 ossifying fibromyxoid tumor 10.5 ENO2 S100B
31 adult hepatocellular carcinoma 10.5 TSC1 TSC2
32 head injury 10.5 ENO2 S100B
33 perineurioma 10.5 GFAP S100B
34 multilocular clear cell renal cell carcinoma 10.4 TSC1 TSC2
35 desmoplastic infantile ganglioglioma 10.4 GFAP SYP
36 extraventricular neurocytoma 10.4 GFAP SYP
37 lung combined type small cell carcinoma 10.4 GFAP SYP
38 cellular ependymoma 10.4 GFAP SYP
39 gangliocytoma 10.4 GFAP SYP
40 rhabdoid meningioma 10.4 GFAP SYP
41 ureter small cell carcinoma 10.4 ENO2 SYP
42 lissencephaly with cerebellar hypoplasia 10.4 TSC1 TSC2
43 pilomyxoid astrocytoma 10.4 GFAP SYP
44 malignant sertoli cell tumor 10.4 ENO2 SYP
45 urinary bladder small cell neuroendocrine carcinoma 10.4 ENO2 SYP
46 auditory system cancer 10.4 ENO2 SYP
47 chiari malformation 10.4 GFAP SYP
48 sinonasal undifferentiated carcinoma 10.4 ENO2 SYP
49 sensory organ benign neoplasm 10.4 ENO2 SYP
50 gallbladder small cell carcinoma 10.4 ENO2 SYP

Graphical network of the top 20 diseases related to Subependymal Giant Cell Astrocytoma:



Diseases related to Subependymal Giant Cell Astrocytoma

Symptoms & Phenotypes for Subependymal Giant Cell Astrocytoma

UMLS symptoms related to Subependymal Giant Cell Astrocytoma:


headache, seizures

MGI Mouse Phenotypes related to Subependymal Giant Cell Astrocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.17 ENO2 GFAP MTOR S100B SYP TSC1

Drugs & Therapeutics for Subependymal Giant Cell Astrocytoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009

Drugs for Subependymal Giant Cell Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
4 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
9
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
11
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
16 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
17 Dermatologic Agents Phase 3,Phase 1
18 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
19 Analgesics Phase 3,Phase 1
20 Central Nervous System Depressants Phase 3
21 Adjuvants, Anesthesia Phase 3
22 Gastrointestinal Agents Phase 3,Phase 1,Not Applicable
23 Narcotics Phase 3
24 Neurotransmitter Agents Phase 3,Early Phase 1,Not Applicable
25 Analgesics, Opioid Phase 3
26 Anesthetics Phase 3
27 Anesthetics, General Phase 3
28 Anesthetics, Intravenous Phase 3
29 Emetics Phase 3
30 Peripheral Nervous System Agents Phase 3,Phase 1
31 Antiemetics Phase 3,Phase 1
32 Liver Extracts Phase 3,Phase 1,Phase 2
33 BB 1101 Phase 3,Phase 2,Phase 1
34 Autonomic Agents Phase 3,Phase 1
35
Histamine Phosphate Phase 3 51-74-1 65513
36 Serotonin Agents Phase 3
37 Serotonin Antagonists Phase 3
38 Histamine Antagonists Phase 3
39 Histamine H1 Antagonists Phase 3
40 Anti-Allergic Agents Phase 3
41 Antipruritics Phase 3
42 Cola Nutraceutical Phase 3
43
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
44
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
45
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
46
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
47
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
48
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
49
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
50
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4 Everolimus;Envirolimus drug class as prescribed by Physician
2 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3 Everolimus;Placebo
3 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
7 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
8 Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex Completed NCT00411619 Phase 1, Phase 2 Everolimus
9 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
10 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
11 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
12 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
13 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
14 A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Recruiting NCT02451696 Phase 2 Everolimus
15 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
16 Bevacizumab in Recurrent Grade II and III Glioma Active, not recruiting NCT01164189 Phase 2 Temozolomide
17 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2 everolimus;temozolomide
18 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
19 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
20 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
21 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
22 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
23 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
24 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
25 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
26 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
27 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
28 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
29 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
30 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
31 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
32 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
33 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
34 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
35 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
36 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
37 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
38 Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
39 Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
40 A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer Recruiting NCT01582191 Phase 1 Vandetanib;Everolimus
41 Anakinra or Denosumab and Everolimus in Advanced Cancer Active, not recruiting NCT01624766 Phase 1 Everolimus;Anakinra;Denosumab
42 Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer Active, not recruiting NCT01087554 Phase 1 Sirolimus;Vorinostat;Everolimus;Temsirolimus
43 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Active, not recruiting NCT02186509 Phase 1 Alisertib
44 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
45 Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors Terminated NCT00112619 Phase 1 topotecan hydrochloride
46 Study of Blood and Cheek Cell Samples From Patients With Glioma Completed NCT01009307
47 Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma Completed NCT00999622
48 Study of Tissue Samples From Patients With Glioma or Other Brain Tumors Completed NCT00967200
49 Metabolic Syndrome in Childhood Cancer Survivors Completed NCT00920738
50 Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors Completed NCT00499798

Search NIH Clinical Center for Subependymal Giant Cell Astrocytoma

Genetic Tests for Subependymal Giant Cell Astrocytoma

Anatomical Context for Subependymal Giant Cell Astrocytoma

MalaCards organs/tissues related to Subependymal Giant Cell Astrocytoma:

41
Brain, Spinal Cord, Endothelial, Breast, Liver, T Cells, Bone

Publications for Subependymal Giant Cell Astrocytoma

Articles related to Subependymal Giant Cell Astrocytoma:

(show top 50) (show all 156)
# Title Authors Year
1
Trapped ventricle after laser ablation of a subependymal giant cell astrocytoma complicated by intraventricular gadolinium extravasation: case report. ( 29451453 )
2018
2
Efficacy and safety of everolimus in patients younger than 12a8^months with congenital subependymal giant cell astrocytoma. ( 29395661 )
2018
3
Atypical subependymal giant cell astrocytoma and neonatal tuberous sclerosis. ( 29555882 )
2018
4
Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomised EXIST-1 and EXIST-2 studies. ( 29569806 )
2018
5
The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. ( 28993887 )
2018
6
Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. ( 29973652 )
2018
7
Subependymal Giant Cell Astrocytoma - A SEER-based Analysis from 2004-2013. ( 29966782 )
2018
8
Subependymal Giant Cell Astrocytoma: Associated Hyperproteinorrhachia Causing Shunt Failures and Nonobstructive Hydrocephalus - Report of Successful Treatment with Long-term Follow-up. ( 29114301 )
2017
9
Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation. ( 28074282 )
2017
10
Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report. ( 28516078 )
2017
11
Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus. ( 28511812 )
2017
12
Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex. ( 28866062 )
2017
13
Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas. ( 28162859 )
2017
14
Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases. ( 27625244 )
2016
15
Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). ( 27860334 )
2016
16
Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis. ( 26942030 )
2016
17
Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature. ( 26861567 )
2016
18
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. ( 27013816 )
2016
19
Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex. ( 26929034 )
2016
20
Subependymal giant cell astrocytoma in a genetically negative tuberous sclerosis complex adult: Case report. ( 27690251 )
2016
21
Thyroid transcription factor-1 distinguishes subependymal giant cell astrocytoma from its mimics and supports its cell origin from the progenitor cells in the medial ganglionic eminence. ( 27910945 )
2016
22
EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. ( 27502586 )
2016
23
Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report. ( 27690646 )
2016
24
Variability of Dose and Level of Sirolimus in a Patient With Tuberous Sclerosis Complex and Subependymal Giant Cell Astrocytoma. ( 27082208 )
2016
25
Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase. ( 27390104 )
2016
26
Retraction Note to: Subependymal giant cell astrocytoma: current concepts, management, and future directions. ( 26922080 )
2016
27
Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. ( 26173783 )
2015
28
Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report. ( 25978531 )
2015
29
Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). ( 25929843 )
2015
30
Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. ( 26706014 )
2015
31
BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. ( 25346165 )
2015
32
The clinical characteristics of subependymal giant cell astrocytoma: five cases. ( 25977907 )
2015
33
Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma. ( 25909870 )
2015
34
Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study. ( 25525770 )
2015
35
Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex. ( 26552385 )
2015
36
Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. ( 26381530 )
2015
37
Thyroid transcription factor-1 and epithelial membrane antigen expression in four cases of subependymal giant cell astrocytoma. ( 25195621 )
2014
38
A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. ( 24180681 )
2014
39
Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. ( 25227171 )
2014
40
Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex. ( 25143481 )
2014
41
Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. ( 24507694 )
2014
42
Subependymal giant cell astrocytoma: current concepts, management, and future directions. ( 24549759 )
2014
43
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. ( 25456370 )
2014
44
An unusually aggressive clinical behavior in a case of atypical subependymal giant cell astrocytoma. ( 25387628 )
2014
45
The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. ( 24729041 )
2014
46
Subependymal Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex:: Considerations for Surgical or Pharmacotherapeutic Intervention. ( 24105488 )
2013
47
The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. ( 23183057 )
2013
48
Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding. Case report and review of literature. ( 23138436 )
2013
49
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. ( 23158522 )
2013
50
Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. ( 23391693 )
2013

Variations for Subependymal Giant Cell Astrocytoma

Expression for Subependymal Giant Cell Astrocytoma

Search GEO for disease gene expression data for Subependymal Giant Cell Astrocytoma.

Pathways for Subependymal Giant Cell Astrocytoma

Pathways related to Subependymal Giant Cell Astrocytoma according to KEGG:

37
# Name Kegg Source Accession
1 mTOR signaling pathway hsa04150

Pathways related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 MTOR TSC1 TSC2
2
Show member pathways
12.27 MTOR TSC1 TSC2
3 12.27 ENO2 GFAP S100B SYP
4
Show member pathways
12.21 MTOR TSC1 TSC2
5
Show member pathways
12.19 MTOR TSC1 TSC2
6
Show member pathways
12.18 MTOR TSC1 TSC2
7
Show member pathways
12.07 MTOR TSC1 TSC2
8 12.04 MTOR TSC1 TSC2
9
Show member pathways
11.98 MTOR TSC1 TSC2
10 11.93 MTOR TSC1 TSC2
11 11.93 MTOR TSC1 TSC2
12 11.9 MTOR TSC1 TSC2
13
Show member pathways
11.88 MTOR TSC1 TSC2
14
Show member pathways
11.86 MTOR TSC1 TSC2
15 11.78 MTOR TSC1 TSC2
16
Show member pathways
11.75 MTOR TSC1 TSC2
17
Show member pathways
11.73 MTOR TSC1 TSC2
18 11.68 MTOR TSC1 TSC2
19 11.51 MTOR TSC1 TSC2
20 11.31 TSC1 TSC2
21 11.3 MTOR TSC2
22 11.28 MTOR TSC1 TSC2
23 11.16 MTOR TSC1 TSC2
24 11.08 MTOR TSC2
25 11.02 MTOR TSC2
26 10.96 MTOR TSC1 TSC2
27 10.82 GFAP NES S100B SYP
28 10.81 MTOR TSC1
29 10.66 MTOR TSC1 TSC2

GO Terms for Subependymal Giant Cell Astrocytoma

Cellular components related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament cytoskeleton GO:0045111 8.96 GFAP NES
2 TSC1-TSC2 complex GO:0033596 8.62 TSC1 TSC2

Biological processes related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of stress fiber assembly GO:0051496 9.51 MTOR TSC1
2 cell cycle arrest GO:0007050 9.5 MTOR TSC1 TSC2
3 long-term synaptic potentiation GO:0060291 9.49 GFAP S100B
4 regulation of protein kinase activity GO:0045859 9.48 MTOR TSC1
5 negative regulation of TOR signaling GO:0032007 9.46 TSC1 TSC2
6 negative regulation of insulin receptor signaling pathway GO:0046627 9.43 TSC1 TSC2
7 positive regulation of macroautophagy GO:0016239 9.4 TSC1 TSC2
8 regulation of neuronal synaptic plasticity GO:0048168 9.37 S100B SYP
9 negative regulation of macroautophagy GO:0016242 9.26 MTOR TSC1
10 positive regulation of glial cell proliferation GO:0060252 9.16 GFAP MTOR
11 anoikis GO:0043276 8.96 MTOR TSC2
12 negative regulation of cell size GO:0045792 8.62 MTOR TSC1

Molecular functions related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp90 protein binding GO:0051879 8.96 TSC1 TSC2
2 binding GO:0005488 8.8 MTOR TSC1 TSC2

Sources for Subependymal Giant Cell Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....